We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+43.68%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.35B
AUM Growth
+$397M
Cap. Flow
+$106M
Cap. Flow %
7.83%
Top 10 Hldgs %
60.29%
Holding
72
New
21
Increased
13
Reduced
7
Closed
23
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.6 years
Top 20 Avg Time Held Equity + Options
0.7 years
Avg Time Held Equity only
0.7 years
Top 10 Avg Time Held Equity only
0.7 years
Top 20 Avg Time Held Equity only
0.7 years

Top Buys

Rank Stock Value
1
ORIC icon
Oric Pharmaceuticals
ORIC
+$84.3M
2
XNCR icon
Xencor
XNCR
+$62.7M
3
RNAM
Avidity Biosciences
RNAM
+$60.7M
4
AKUS
Akouos Inc
AKUS
+$44M
5
RCUS icon
Arcus Biosciences
RCUS
+$41M

Top Sells

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$61.6M
2
FATE icon
Fate Therapeutics
FATE
+$51.3M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$45M
4
KYNB icon
Kyntra Bio
KYNB
+$30.7M
5
IPHA icon
Innate Pharma
IPHA
+$29.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.14%
2 Miscellaneous 2.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
STRO icon
26
Sutro Biopharma
STRO
$181M
$14.2M 1.05%
+182,849
New +$17.5M
2020 Q2
0 quarters
CNST
27
CALL
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$12M 0.89%
+400,000
New +$14.4M
2020 Q2
0 quarters
RLMD icon
28
Relmada Therapeutics
RLMD
$331M
$8.95M 0.66%
+200,000
New +$8.46M
2020 Q2
0 quarters
KROS icon
29
Keros Therapeutics
KROS
$211M
$8.26M 0.61%
+220,216
New +$6.78M
2020 Q2
0 quarters
CBIO icon
30
Crescent Biopharma
CBIO
$440M
$7.1M 0.52%
+18,890
New +$5.35M
2020 Q2
0 quarters
ACAD icon
31
Acadia Pharmaceuticals
ACAD
$3.29B
$6.56M 0.48%
135,413
-188,476
-58% -$9.05M
2019 Q4
2 quarters
EVLO
32
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$6.13M 0.45%
+62,500
New +$5.47M
2020 Q2
0 quarters
PRVL
33
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$5.47M 0.4%
367,218
-1,881,088
-84% -$29M
2019 Q2
4 quarters
IRWD icon
34
CALL
Ironwood Pharmaceuticals
IRWD
$578M
$5.16M 0.38%
+500,000
New +$5.12M
2020 Q2
0 quarters
XCUR icon
35
Exicure
XCUR
$7.33M
$4.08M 0.3%
11,155
-7,787
-41% -$2.82M
2019 Q3
3 quarters
SVRA icon
36
Savara
SVRA
$914M
$3.57M 0.26%
1,432,664
– –
2019 Q4
2 quarters
DNTH icon
37
Dianthus Therapeutics
DNTH
$4.03B
$3.38M 0.25%
+28,125
New +$3.96M
2020 Q2
0 quarters
LSACU
38
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
$3.3M 0.24%
300,000
– –
2020 Q1
1 quarter
ACRS icon
39
Aclaris Therapeutics
ACRS
$483M
$2.48M 0.18%
1,531,312
-556,000
-27% -$745K
2019 Q4
2 quarters
RPRX icon
40
Royalty Pharma
RPRX
$27.1B
$2.43M 0.18%
+50,000
New +$2.47M
2020 Q2
0 quarters
FPRX
41
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$2.32M 0.17%
379,945
+123,870
+48% +$510K
2020 Q1
1 quarter
CRVS icon
42
Corvus Pharmaceuticals
CRVS
$801M
$2.01M 0.15%
737,612
– –
2019 Q4
2 quarters
RPTX icon
43
DELISTED
Repare Therapeutics
RPTX
$1.55M 0.11%
+50,000
New +$1.61M
2020 Q2
0 quarters
ICPT
44
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.21M 0.09%
+25,300
New +$1.95M
2020 Q2
0 quarters
MGTX icon
45
MeiraGTx Holdings
MGTX
$891M
$1.19M 0.09%
94,819
– –
2020 Q1
1 quarter
XOMA icon
46
DELISTED
Xoma
XOMA
$1M 0.07%
50,809
– –
2020 Q1
1 quarter
KLDO
47
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$233K 0.02%
+31,374
New +$210K
2020 Q2
0 quarters
EQ icon
48
Equillium
EQ
$75.5M
$174K 0.01%
+59,014
New +$168K
2020 Q2
0 quarters
PLRX icon
49
Pliant Therapeutics
PLRX
$55.7M
$42K ﹤0.01%
+1,300
New +$34.5K
2020 Q2
0 quarters
ARVN icon
50
Arvinas
ARVN
$456M
– –
-1,528,031
Closed -$61.6M –
1
2
3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2020 Portfolio in Review

As of Q2 2020, EcoR1 Capital held 72 positions worth $1.35B, up 41% from $957M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

EcoR1 Capital deployed $106M of net new capital in Q2 2020, opening 21 new positions and adding to 13 existing holdings. Its largest new stake was Oric Pharmaceuticals: 2,642,218 shares worth $89.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Fate Therapeutics, an estimated $51.3M trimmed.

  • EcoR1 Capital's largest Q2 2020 buy was Oric Pharmaceuticals: 2,642,218 shares worth $89.1M.
  • EcoR1 Capital added most to Xencor in Q2 2020, an estimated $62.7M increase.
  • EcoR1 Capital's biggest Q2 2020 reduction was Fate Therapeutics, cutting an estimated $51.3M.
  • EcoR1 Capital fully exited Arvinas in Q2 2020, selling an estimated $61.6M.
  • EcoR1 Capital's ten largest holdings make up 60% of its $1.35B portfolio in Q2 2020.
  • EcoR1 Capital opened 21 new positions and closed 23 in Q2 2020.
  • EcoR1 Capital's portfolio value rose 41% quarter-over-quarter to $1.35B.

Based on EcoR1 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.